Novavax Inc Is It Worth Waiting For Novavax's (NASDAQ: NVAX) Vaccine Candidate? Novavax Inc. (NASDAQ: NVAX) is preparing to get authorization for its coronavirus vaccine. The firm is currently near the finish line and will soon join the Pfizer/BioNTech, and Moderna in launching the vaccine to stop the spread of the novel virus.
Novavax Inc Novavax (NASDAQ: NVAX) Strikes 51M COVID Vaccine Doses Deal With Australia Novavax, Inc. (NASDAQ: NVAX) has completed the COVID-19 vaccine supply deal with the Commonwealth of Australia. As per the deal, Novavax is scheduled to provide 50 million doses of its COVID-19 vaccine candidate to Australia as early as mid-2021.
$NVAX Novavax (NASDAQ: NVAX) Announces Delay In Coronavirus Trial Novavax, Inc. (NASDAQ: NVAX) has provided updates regarding its late-stage coronavirus study. The company has disclosed that it is planning to commence Phase III Clinical trial in Mexico and the US in the coming week. NVAX has also arranged alternative clinical sites to use
